Androgen Receptor Mutation Detection for Prostate Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate and breast cancers associated with Androgen Receptor (AR) mutations, particularly the F877 mutation, develop resistance to MDV3100, leading to ineffective therapies and the need for novel stratification methods and therapeutics.
Innovation Solution
Development of therapeutic compositions and methods involving CDK4/6 inhibitors like LEE011, and detection of specific AR mutations at positions F877, W742, and T878 to tailor treatments, including the use of polypeptides, antibodies, and polynucleotides to target these mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDV3100 is used to treat prostate cancer with AR mutations, then initial treatment efficacy is improved, but resistance develops leading to treatment failure
Solution Approach 1:
The patent applies preliminary action by detecting AR mutations (F877, W742, T878) before initiating MDV3100 treatment. This allows identification of patients who would develop resistance, enabling selection of alternative therapies upfront rather than waiting for treatment failure. The mutation detection serves as a preliminary筛选 mechanism to prevent ineffective treatment assignment.
Solution Approach 2:
The patent employs parameter changes by using genetic biomarkers (amino acid sequences at specific positions) to stratify patients into different treatment groups. This changes the treatment parameter from a one-size-fits-all approach to a personalized approach based on molecular characteristics, thereby improving overall treatment efficacy and preventing resistance in susceptible patients.
2Reliability
If anti-androgen therapy is used to block AR signaling, then tumor growth is initially inhibited, but antagonist-to-agonist switch occurs enhancing AR signaling
Solution Approach 1:
The patent applies preliminary anti-action by detecting AR mutations that predispose patients to antagonist-to-agonist switch before treatment begins. This allows selection of alternative therapeutic mechanisms (such as CDK4/6 inhibitors or other non-anti-androgen approaches) that would not trigger the harmful paradoxical effect, thereby preventing rather than treating the problem.
Solution Approach 2:
The patent converts the harmful effect of antagonist-to-agonist switch into a beneficial diagnostic tool. The presence of specific mutations (F877, W742, T878) that cause this switch is used as a biomarker to identify patients who should receive alternative therapies. The mutation that would normally be harmful becomes a useful indicator for personalized treatment selection.
3Ease of operation
If standardized treatment protocols are applied to all prostate cancer patients, then treatment simplicity is maintained, but individual patient responses vary due to genetic differences
Solution Approach 1:
The patent applies local quality by tailoring treatment to the specific genetic characteristics of each patient's AR gene. Instead of uniform treatment, patients are stratified based on local genetic variations (mutations at positions F877, W742, T878) and assigned to different therapeutic regimens. This localized approach to treatment selection improves response reliability while maintaining operational feasibility through standardized testing protocols.
Solution Approach 2:
The patent implements parameter changes by using genetic biomarkers to divide the patient population into distinct subgroups with different treatment optima. This transforms the treatment parameter from a single standardized protocol to multiple protocol options based on molecular parameters, thereby improving individual patient responses while maintaining systematic approach through standardized testing.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 876 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 741 and 877 is also shown to be useful for patient stratification.